Journey II BCS EU Observational Trial

Sponsor
Smith & Nephew Orthopaedics AG (Industry)
Overall Status
Active, not recruiting
CT.gov ID
NCT02211794
Collaborator
(none)
175
5
149
35
0.2

Study Details

Study Description

Brief Summary

Post-market study to confirm the safety and efficacy of the Journey II BCS knee prosthesis.

Condition or Disease Intervention/Treatment Phase
  • Other: data collection

Detailed Description

Multicenter, prospective, observational study to collect relevant clinical data from 167 subjects implanted with the Journey II BCS Knee System. Data from eligible subjects, who have provided written informed consent for the collection of their coded data will be recorded from the patient's medical file on specially designed case report forms (CRF's).

Total study duration for participants will be 10 years with follow-up visits planned at 3 months, 1 year, 2 years, 5 years and 10 years post-surgery. An interim analysis describing the clinical outcome is planned after 5 years.

Study Design

Study Type:
Observational
Actual Enrollment :
175 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Prospective, Non-randomized, Consecutive Series, Multicenter, Observational Trial to Evaluate the Clinical Outcome of Total Knee Arthroplasty Using Journey II BCS Total Knee System
Study Start Date :
Jan 1, 2014
Anticipated Primary Completion Date :
Jun 1, 2026
Anticipated Study Completion Date :
Jun 1, 2026

Arms and Interventions

Arm Intervention/Treatment
1 cohort

subject requires primary total knee arthroplasty with the Journey II BCS Total Knee System, including patella resurfacing due to degenerative joint disease (primary osteoarthritis, post-traumatic arthritis, avascular necrosis, rheumatoid arthritis)

Other: data collection

Outcome Measures

Primary Outcome Measures

  1. Revision for any reason [10Years]

    The goal of this study is to confirm the safety and efficacy of the Journey II BCS knee prosthesis by demonstrating non-inferiority of the cumulative percent success in subjects implanted with the JOURNEY II BCS Total Knee System compared to a literature reference rate of 94.3% (AOA annual report 201121) at 10 years. "Success" is defined as 10 year survival of the study device without revision for any reason.

Secondary Outcome Measures

  1. EQ-5D questionnaire [pre-op, 3month, 1yr, 2yr, 5yr, 10yr]

    patient's opinion about his state of health, according to a visual analogue scale and 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression, (each dimension having 3 levels: no problems, some problems, extreme problems)

  2. Knee Pain Evaluation Form questionnaire [3month, 1yr, 2yr]

    Assessment of post-operative knee pain

  3. 2011 Knee Society Score [pre-op, 3month, 1yr, 2yr, 5yr, 10yr]

    A clinical follow-up and patient satisfaction, patient's expectations and a self-assessment of the physical outcome

  4. radiographic evaluation [pre-op, discharge, 3month, 1yr, 5yr, 10yr]

    The Knee Society Total Knee Arthroplasty Roentographic Evaluation and Scoring System will be used to analyse radiographic findings at each visit.

  5. complication rate (adverse events and revisions) [discharge, 3month, 1yr, 2yr, 5yr, 10yr]

    complications will be assessed at each visit.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

Inclusion Criteria

  • subject requires primary total knee arthroplasty with the Journey II BCS Total Knee System, including patella resurfacing

  • subject requires primary total knee arthroplasty due to degenerative joint disease (primary osteoarthritis, post-traumatic arthritis, avascular necrosis, rheumatoid arthritis)

  • subject is of legal age to consent, agrees to consent to and to follow the study visit schedule, by signing the EC approved informed consent form

Exclusion Criteria:
  • age > 75 years

  • conditions that may interfere with the TKA survival or outcome (i.e., Paget's or Charcot's disease, vascular insufficiency, muscular atrophy, uncontrolled diabetes, moderate to severe renal insufficiency or neuromuscular disease)

  • subject has inadequate bone stock to support the device

Contacts and Locations

Locations

Site City State Country Postal Code
1 UZ Gent Gent Belgium 9000
2 University of Modena and Reggio Emilia Modena Italy 41124
3 Sint Maartenskliniek Nijmegen Netherlands 9500
4 Martina Hansens Hospital Sandvika Norway
5 North Hampshire Hospital Basingstoke United Kingdom RG24 7AL

Sponsors and Collaborators

  • Smith & Nephew Orthopaedics AG

Investigators

  • Principal Investigator: Mike Risebury, MD, North Hampshire Hospital
  • Study Chair: Fabio Catani, Prof, University of Modena and Reggio Emilia
  • Principal Investigator: Jan Victor, Prof, UZ Ghent
  • Principal Investigator: Gijs Van Hellemondt, Sint-Maartenskliniek Nijmegen
  • Principal Investigator: Stig Heir, Martina Hansens Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Smith & Nephew Orthopaedics AG
ClinicalTrials.gov Identifier:
NCT02211794
Other Study ID Numbers:
  • R11009-7
First Posted:
Aug 7, 2014
Last Update Posted:
Dec 14, 2021
Last Verified:
Dec 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Smith & Nephew Orthopaedics AG
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 14, 2021